 corynebacterium parvum versu calmette-guerin adjuv immunotherapi stage II malign melanoma separ studi corynebacterium parvum calmette-guerin bcg adjuv immunotherapi stage II melanoma patient milton hershey medic center patient southeastern cancer studi group secsg patient criteria patient select drug similar data effect treatment studi bcg tice chicago IL organ treatment tine techniqu parvum burroughs-wellcom triangl park NC dose secsg hershey treatment differ studi frequenc immun patient hershey dose secsg patient dose period treatment kaplan-mei life-t analysi patient prolong disease-fre interv patient parvum two-sid mantel procedur similar fashion patient parvum surviv rate caus bcg-treat patient analysi result patient number posit node avail cox model node stratif variabl covari place treatment age sex analysi observ benefit parvum disease-fre interv valu benefit parvum surviv time caus valu analysi patient year observ benefit parvum disease-fre interv valu benefit parvum surviv time caus valu